Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Company Leadership Changes - Jasper Therapeutics has appointed Jeet Mahal as President and Chief Executive Officer, effective January 5, 2026, succeeding Ronald Martell [2][3] - Thomas Wiggans has been appointed as the Executive Chairperson of the Board of Directors [2][3] Strategic Focus and Development - The company is preparing to commence the registrational program for briquilimab, targeting mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [3][4] - Mr. Mahal brings over thirty years of experience in the life sciences industry, with a focus on developing therapeutics and leading biotech companies through clinical trials [3][4] Upcoming Events - Jasper will host an investor webinar on January 8, 2026, at 8:00 a.m. ET to present updated data from the BEACON study and the open-label extension study in CSU and CIndU [2][5] - A live question and answer session will follow the formal presentation during the webinar [5][6] Product Development - Briquilimab is a targeted monoclonal antibody that inhibits signaling through the KIT receptor, aiming to deplete mast cells and address inflammatory responses in diseases like CSU and asthma [7][8] - The drug has shown efficacy and safety in clinical studies involving patients and healthy volunteers, with positive outcomes reported in CSU, CIndU, and allergic asthma [8]